View Clinical Trial (Medical Research Study)

Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris - NCT00673933-60563(Clinical Trial 219340)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Naperville
State:  
IL
Zip Code: 60563
Conditions: Acne Vulgaris
Purpose: In this multicenter study, patients with dark skin and acne vulgaris will be included. The patients will receive treatment with MAL PDT and placebo PDT.
Study summary:
Criteria: Inclusion Criteria: 1. Female and male patients, age 15 to 40 years with acne vulgaris. 2. Patients with skin type V or VI (Fitzpatrick). 3. Patients with two areas of each 8x8 cm2 on the back that include at least 5 inflammatory lesions (papules, pustules, and nodules) each. The minimum distance between the two areas should be at least 4 cm. 4. Patients with no more than 2 nodular lesions in any of the two areas of each 8x8 cm2 on the back. 5. Patients who are surgically sterile, postmenopausal, abstinent, or willing to use an adequate means of contraception including birth control pills, or barrier methods and spermicide for at least 14 days prior to Day 0. Patients using birth control pills must have used the same product and dose for at least 3 months and must agree to stay with the same product and dose for an additional 3 months. 6. Patients must be willing and capable of following study instructions to the extent and degree required by the protocol. 7. Patients must sign the approved informed consent form prior to any study procedures. 8. Patients must be willing to be photographed. Patients must be willing to sign a photography consent form. Exclusion Criteria: 1. Known allergy to MAL, to a similar PDT compound, or to excipients of the cream. 2. Participation in other clinical studies either concurrently or within the last 30 days. 3. Patients who have a condition or who are in a situation, which, in the investigator's opinion, may put the patient at risk, may confound the study results, or may interfere with the patient's participation in the study. 4. Clinically significant sensitivity to visible light, or has porphyria or porphyrin sensitivity. 5. Exposure to ultraviolet radiation (UVB phototherapy) within the last 30 days. 6. Patients with a washout period for topical treatments for their acne in the two treatment areas of less than 14 days. Any topical treatment on the face or other areas outside the two treatment areas will be allowed. 7. Patients with a washout period for oral antibiotics for treatment of their acne of less than 1 month. 8. Patients with a washout period for oral isotretinoin of less than 6 months.
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: December 30, 2009
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.